相关实验视频
Updated: May 14, 2025

A Porcine Model of Acute Autologous Pulmonary Embolism
Published on: September 6, 2024
肺栓塞的临床特征在极高的高度:一个单中心的回顾性研究
Jialin Wu1, Jianli Zhang1, Rui Wang2
1Department of Respiratory Disease, General Hospital of Xinjiang Military Command, Ürümqi, China.
高空暴露增加了静脉血栓栓塞 (VTE) 的风险. 这项研究发现,处于极高海拔地区的肺栓塞 (PE) 患者的血液标志物较高,凝块分离速度更快,这表明尿酸等独特的危险因素.
科学领域:
- 心血管医学 心血管医学
- 高度生理学 高度生理学
- 血液学 血液学 血液学
背景情况:
- 高空 (HA) 暴露与静脉血栓栓塞 (VTE) 风险增加有关.
- 在极高处出现VTE的临床特征尚不清楚.
- 肺栓塞 (PE) 是一种关键形式的VTE.
研究的目的:
- 为了比较PE患者在极高海拔地区和低海拔地区的临床特征和预后.
- 在高海拔环境中调查PE的潜在风险因素.
主要方法:
- 从2019年11月到2022年11月对PE患者的回顾性分析.
- 在一个高海拔群 (HA-Group,>5000m) 和一个低海拔群 (LA-Group,<1000m) 之间的比较.
- 血液学指标的分析和到肺血栓形成的时间.
主要成果:
- 与LA组 (n=62) 相比,HA组 (n=17) 的红血球,淋巴细胞,血小板,血红蛋白,PT,APTT,INR和尿酸水平显著更高.
- 肺血栓瘤完全消失的时间在HA组显著缩短.
- HA组的平均高度为5041米,而LA组的平均高度为802米.
结论:
- 极高的高度暴露与明显的PE临床特征有关.
- 高空暴露可能会增加对PE的易感性,特别是在年轻人中.
- 血清尿酸代谢异常是高海拔地区PE的潜在危险因素.
更多相关视频
07:41Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
Published on: March 17, 2022
09:54Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death
Published on: August 15, 2022
相关概念视频
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Pneumothorax-II
Clinical Manifestations:
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Pneumothorax-I
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD: